The first reported clinical trial that demonstrated biological activity of CAR T cells in AML was published in 2013 by Ritchie et al. utilizing a second generation CD28-ζ CAR directed against the Lewis Y antigen. The gene discussed is CD28; the disease is acute myeloid leukemia.